IL-13 and IL-17A activate β1 integrin through an NF-kB/Rho kinase/PIP5K1γ pathway to enhance force transmission in airway smooth muscle
收藏DataONE2025-03-11 更新2025-04-26 收录
下载链接:
https://search.dataone.org/view/sha256:3ce8c704f6bdc84b96ca5cc6d149c5668dcf11bb0951de04200c4cda69ddca1d
下载链接
链接失效反馈官方服务:
资源简介:
Integrin activation resulting in enhanced adhesion to the extracellular matrix plays a key role in fundamental cellular processes. Although integrin activation has been extensively studied in circulating cells such as leukocytes and platelets, much less is known about the regulation and functional impact of integrin activation in adherent cells such as smooth muscle. Here, we show that two different asthmagenic cytokines, IL-13 and IL-17A, activate type I and IL-17 cytokine receptor families, respectively, to enhance adhesion of airway smooth muscle. These cytokines also induce activation of β1 integrins detected by the conformation-specific antibody HUTS-4. Moreover, HUTS-4 binding is increased in the smooth muscle of patients with asthma compared to nonsmokers without lung disease, suggesting a disease-relevant role for integrin activation in smooth muscle. Indeed, integrin activation induced by the β1-activating antibody TS2/16, the divalent cation manganese, or the synthetic peptide..., , , # Data from: IL-13 and IL-17A activate β1 integrin through an NF-kB/Rho kinase/PIP5K1γ pathway to enhance force transmission in airway smooth muscle
([https://doi.org/10.1073/pnas.2401251121](https://doi.org/10.1073/pnas.2401251121))
## Description of data files
### Figure 1 folder
#### File: Figure 1A and 1B.xlsx
**Description:** Data for adhesion assay as measured by absorbance of crystal violet at 595 nm of Human Airway Smooth Muscle (HASM) cells to various concentrations of collagen and fibronectin after treatment with vehicle, IL-13 (100 ng/mL), or IL-17A (100 ng/mL) for 12 h.
#### Folder:Figure 1C
**Description:** Contains flow cytometry data (file type:fcs) comparing the expression of active beta-1 integrin in HASM cells treated with vehicle, IL-13 (100 ng/mL), IL-17A (100 ng/mL) for 12 h, or Mn2+ (1 mM) for 20 min followed by labeling with antibody specific for active beta-1 integrin (HUTS-4) and secondary (2°) conjugated to allophycocyanin (APC).
#### Folder: Figure 1D
...,
创建时间:
2025-03-13



